Travere Therapeutics (TVTX) Cash from Operations (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Cash from Operations came in at 40366000.0 in Q1 2026, up 4.33% YoY from 38689814.27 in Q1 2025, and down 166.52% on a QoQ basis from 60678000.0 in Q4 2025.
Travere Therapeutics (TVTX) Cash from Operations (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Cash from Operations data on file, last reported at 40366000.0 in Q1 2026.
- Quarterly Cash from Operations rose 4.33% year-over-year to 40366000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39612000.0 (up 124.64% YoY) and the FY2025 annual result came in at 37784000.0, up 115.91% from the prior year.
- Cash from Operations retreated to 40366000.0 in Q1 2026, from 60678000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 60678000.0 in Q4 2025 to a low of 118902000.0 in Q1 2024.
- A 5-year average of 44217941.18 and a median of 42145000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 666.59% — and 2025, when it surged 268.17%.
- Tracing TVTX's Cash from Operations over 5 years: stood at 54640000.0 in 2022, then sank by 111.95% to 115809000.0 in 2023, then jumped by 68.84% to 36082000.0 in 2024, then surged by 268.17% to 60678000.0 in 2025, then sank by 166.52% to 40366000.0 in 2026.
- The last three Cash from Operations figures came in at 40366000.0 (Q1 2026), 60678000.0 (Q4 2025), and 14317000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 58.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.07 Mn |
| Jun 30, 2026 | 58.07 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Dec 31, 2025 | 60.68 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.98 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Mar 31, 2025 | -42.19 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Dec 31, 2024 | -36.08 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Jun 30, 2024 | -40.35 Mn |
| Jun 30, 2024 | -40.35 Mn |
| Mar 31, 2024 | -118.90 Mn |
| Mar 31, 2024 | -118.90 Mn |